Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00438659 · ClinicalTrials.gov registry record · Phase 3
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
A Phase 3 study of Breast Cancer and Radiation Toxicity, sponsored by North Central Cancer Treatment Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00438659 is a Phase 3 study of Breast Cancer and Radiation Toxicity that has completed, run by North Central Cancer Treatment Group. The registered enrollment target is 176 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 1 state.
The verdict
NCT00438659, a Phase 3 study of Breast Cancer and Radiation Toxicity, has completed, sponsored by North Central Cancer Treatment Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation dermatitis. PURPOSE: This randomized phase III trial is studying mometasone furoate to see how well it works compared to a placebo in preventing radiation dermatitis in patients undergoing radiation therapy to the breast or chest wall for invasive breast cancer or ductal carcinoma in situ.
Conditions Studied
Interventions
- OTHER placebo
- DRUG mometasone furoate
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
- Galesburg Clinic, PC - Galesburg
- Galesburg Cottage Hospital - Galesburg
- InterCommunity Cancer Center of Western Illinois - Galesburg
- Mason District Hospital - Havana
- Hopedale Medical Complex - Hopedale
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Kewanee Hospital - Kewanee
- McDonough District Hospital - Macomb
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus - Moline
- - Moline
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
- Community Hospital of Ottawa - Ottawa
- Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
- Cancer Treatment Center at Pekin Hospital - Pekin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2007-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00438659
The ClinicalTrials.gov registry entry for NCT00438659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is North Central Cancer Treatment Group, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00438659 reports 20 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00438659 about?
NCT00438659 is a clinical study titled "Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ". RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation dermatitis. PURPOSE: This randomized phase III trial is studying mometasone f...
What is the current status of trial NCT00438659?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2007-08. Estimated completion is 2014-06.
What conditions does trial NCT00438659 study?
This clinical trial studies the following conditions: Breast Cancer, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy, Dermatologic Complications.
What interventions are being tested in trial NCT00438659?
The interventions under investigation include: placebo (OTHER), mometasone furoate (DRUG).
Who is sponsoring clinical trial NCT00438659?
This trial is sponsored by North Central Cancer Treatment Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00438659 being conducted?
This trial has 20 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.